Objective: Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening infectious disease.
Treatment requires multiple antimicrobial agents used for extended periods of time. The …

Multidrug-resistant tuberculosis (MDR-TB), a major global health concern, requires long-
term treatment with multiple drugs, which can cause many side-effects [1]. Therefore, an …

Abstract Background Drug-Resistant Tuberculosis (DR-TB) patients for whom a WHO
recommended regimen along with Bedaquiline (BDQ) cannot be prescribed, Delamanid …

Tuberculosis (TB) remains a significant cause of death worldwide, and emergence of drug-
resistant TB requires lengthy treatments with toxic drugs that are less effective than their first …

The research and development of delamanid was carried out by Otsuka Pharmaceutical
Development and Commercialization (Osaka, Tokyo, Japan). It belongs to the group of …

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) represent
a therapeutic challenge [1]. Two anti-TB agents, bedaquiline and delamanid, have been …

Over 480 000 cases of multidrug-resistant (MDR) tuberculosis (TB) occur every year
globally, 9% of them being affected by extensively drug-resistant (XDR) strains of …

Treatment of multidrug-resistant tuberculosis (MDR-TB) cases is challenging because it
relies on second-line drugs that are less potent and more toxic than those used in the …

The new drugs delamanid and bedaquiline are increasingly used to treat multidrug-resistant
(MDR-) and extensively drug-resistant tuberculosis (XDR-TB). As evidence is lacking, the …

Treatment outcomes for multidrug-resistant (MDR) tuberculosis (TB) are poor with only
approximately 50% of patients attaining treatment success [1]. An important driver of …